2型糖尿病对慢性淋巴细胞白血病患者死亡率、死因及治疗的影响
研究基于丹麦国家登记和Mayo Clinic慢性淋巴细胞白血病资源两个队列平行分析,丹麦队列2型糖尿病患病率为11%,Mayo队列为12%。合并2型糖尿病的慢性淋巴细胞白血病患者自诊断和一线治疗起的总体生存期更短,接受慢性淋巴细胞白血病治疗的可能性更低,死亡风险增加主要由感染死亡风险增加驱动,尤其在丹麦队列中。
要点
- 丹麦队列2型糖尿病患病率11%,Mayo队列为12%。
- 合并2型糖尿病的慢性淋巴细胞白血病患者自诊断和一线治疗起总体生存期更短。
- 合并2型糖尿病患者接受慢性淋巴细胞白血病治疗的可能性更低,死亡风险增加主要由感染死亡驱动。
核心结论
- 合并2型糖尿病的慢性淋巴细胞白血病患者预后较差,可能存在未被满足的治疗需求,需要额外干预和进一步研究。
研究设计与样本
- 基于丹麦国家登记和Mayo Clinic慢性淋巴细胞白血病资源的两个独立队列平行分析。
- 主要结局为自慢性淋巴细胞白血病诊断起的总体生存期、自治疗起的总体生存期和至首次治疗时间,采用Cox比例风险回归分析和Fine-Gray回归分析。
主要发现
- 丹麦慢性淋巴细胞白血病队列中2型糖尿病患病率为11%,Mayo慢性淋巴细胞白血病队列中为12%。
- 合并2型糖尿病的慢性淋巴细胞白血病患者自诊断起和自一线治疗起总体生存期均更短。
- 合并2型糖尿病的慢性淋巴细胞白血病患者接受慢性淋巴细胞白血病治疗的可能性更低。
- 死亡风险增加主要由感染死亡风险增加驱动,尤其在丹麦队列中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Age-related comorbid conditions are exceedingly common in patients with chronic lymphocytic leukemia (CLL). As the prevalence of type 2 diabetes (T2D) is predicted to double during the next two decades, a better understanding of the interplay between CLL and T2D is of increasing importance. In this study, analyses were performed in parallel in two separate cohorts, based on Danish national registers and the Mayo Clinic CLL Resource. The primary outcomes were overall survival (OS) from time of CLL diagnosis, OS from time of treatment, and time to first treatment (TTFT), studied using Cox proportional hazard regression analysis and Fine-Gray regression analysis. In the Danish CLL cohort, the prevalence of T2D was 11%, in the Mayo CLL cohort, it was 12%. Patients with CLL and T2D had shorter OS both from time of diagnosis and from first-line treatment for were less likely to receive treatment for CLL compared with patients with CLL and without T2D. The increased mortality was largely driven by an increased risk of death due to infections, especially in the Danish cohort. The findings of this study emphasize a substantial subgroup of CLL patients with co-occurring T2D with an inferior prognosis and a possible unmet treatment need requiring additional interventions and further research.
引用
- Rotbain EC, Allmer C, Rostgaard K, et al. Impact of type 2 diabetes on mortality, cause of death, and treatment in chronic lymphocytic leukemia. Am J Hematol. 2023. PMID: 37212419. doi:10.1002/ajh.26964
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。